CRVO
CervoMed Inc.
$2.91
-1.02%
$26.9M
No data for this timeframe.
Vol
Market Cap$26.9M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders5 funds
Inst. Value$6.7M
Inst. Activity0 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports6
Press Releases1
Recent Activity
Jun 7, 2026
clinical_trial_readout
Results Pending: neflamapimod (Phase 2) — Completed 88d ago
Trial: A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor: EIP Phar
May 18, 2026
SEC
CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9M, providing runway
8-K — Impact 6/10
May 18, 2026
SEC
CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened to -$8.0M from -$4.9
PRESS-RELEASE — Impact 6/10
Apr 22, 2026
SEC
CervoMed announced positive Phase 2b trial data showing neflamapimod increased basal forebrain volume and functional con
8-K — Impact 7/10
Feb 11, 2026
Insider
Winton Matthew sold 30,000 shares
Chief Commercial and Business @ $0.00 ($0.00)
Feb 11, 2026
Insider
ALAM JOHN J sold 75,000 shares
CEO & President @ $0.00 ($0.00)
Feb 11, 2026
Insider
De Rosch Mark sold 30,000 shares
EVP, RA and GA and PgM @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
12,512 shares ($98.8K)
Price Targets
$20.33
+603.6% upside
Strong Buy
Current $2.89
Low $9.00
Median $20.50
High $27.00
6 analysts
$9.00
$27.00
Analyst Ratings
2Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 22, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Roth Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.79 ▼ -35.0% | $-0.98 — $-0.39 | -12% YoY | 6 |
| Next Q | $-0.58 ▼ -12.8% | $-1.04 — $-0.30 | 30% YoY | 6 |
| Current FY | $-2.68 ▼ -12.3% | $-4.34 — $-1.75 | 10% YoY | 6 |
| Next FY | $-2.42 ▼ -42.8% | $-4.60 — $-1.36 | 10% YoY | 5 |
Latest Reports
BEARISH
8-K
6/10
CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9M, providing runway
May 18, 2026
MIXED
PRESS-RELEASE
6/10
CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened to -$8.0M from -$4.9
May 18, 2026
MIXED
Press
6/10
CervoMed reported full-year 2025 financial results and corporate updates, highlighting positive Phase 2b data for its le
Mar 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $3.7M | DOUBLED |
| VANGUARD GROUP INC | $2.8M | — |
| TWO SIGMA INVESTMENTS, LP | $98.8K | TRIM |
| FMR LLC | $89.5K | DOUBLED |
| BANK OF AMERICA CORP | $95.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 11, 2026 | Winton Matthew | A | $0.00 |
| Feb 11, 2026 | ALAM JOHN | A | $0.00 |
| Feb 11, 2026 | De Rosch | A | $0.00 |
| Feb 11, 2026 | ELDER WILLIAM | A | $0.00 |
| Feb 11, 2026 | Blackburn Kelly | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
5 institutional holders with $6.7M total value (853,294 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, TWO. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 474,494 | $3.7M | 55.6% | DOUBLED +173.8% |
| 2 | VANGUARD GROUP INC | 354,950 | $2.8M | 41.6% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 12,512 | $98.8K | 1.5% | TRIM -26.9% |
| 4 | FMR LLC | 11,326 | $89.5K | 1.3% | DOUBLED +1007.9% |
| 5 | BANK OF AMERICA CORP /DE/ | 12 | $95.00 | 0.0% | NEAR_EXIT -98.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 17,108 | 12,512 | -26.9% | $98.8K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 17,108 | — | $138.4K | 2025-Q3 |
| UBS Group AG | TRIM | 5,593 | 3,376 | -39.6% | $27.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 880 | 12 | -98.6% | $97.00 | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 137,057 | 375,290 | +173.8% | $2.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 3,665 | 880 | -76.0% | $5.5K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,579 | 131 | -94.9% | $823.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 12,722 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 50,628 | 137,057 | +170.7% | $1.3M | 2025-Q1 |
| FMR LLC | DOUBLED | 1,052 | 11,655 | +1007.9% | $106.6K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 43,365 | 6,787 | -84.3% | $62.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 10,811 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 2,537 | 43,365 | +1609.3% | $101.5K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 1,664 | 2,523 | +51.6% | $5.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 47,933 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 7,667 | 45,103 | +488.3% | $658.5K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 12,722 | — | $185.7K | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | Winton Matthew | Chief Commercial and Business | A | 30,000 | $0.00 | $0.00 |
| Feb 11, 2026 | ALAM JOHN J | CEO & President | A | 75,000 | $0.00 | $0.00 |
| Feb 11, 2026 | De Rosch Mark | EVP, RA and GA and PgM | A | 30,000 | $0.00 | $0.00 |
| Feb 11, 2026 | ELDER WILLIAM ROBERT | CFO, GC & Secretary | A | 30,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Blackburn Kelly | EVP, Clinical Development | A | 30,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Gregoire Sylvie | Director | A | 75,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 2 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
8-K
6/10
CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9
May 18, 2026
MIXED
PRESS-RELEASE
6/10
CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened
May 18, 2026
BULLISH
8-K
7/10
CervoMed announced positive Phase 2b trial data showing neflamapimod increased basal forebrain volum
Apr 22, 2026
MIXED
PRESS-RELEASE
6/10
CervoMed Inc. (CRVO) presented new MRI data from its RewinD-LB Phase 2b trial showing that neflamapi
Apr 22, 2026
NEUTRAL
8-K
4/10
CervoMed Inc. announced a clinical update on its neflamapimod program for dementia with Lewy bodies
Apr 7, 2026
BULLISH
8-K
7/10
CervoMed announced the successful completion of a Phase 1 study for a new, stable crystal form of it
Mar 4, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 2 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.33 mean target
+603.6% upside
Strong Buy (3.00)
$9.00 Low
$27.00 High
| Metric | Value |
|---|---|
| Current Price | $2.89 |
| Target Low | $9.00 |
| Target Mean | $20.33 |
| Target Median | $20.50 |
| Target High | $27.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.79 | $-0.98 | $-0.39 | -12.1% | -35.0% | 1↑ 3↓ | $0.0B | -97.6% | 6 |
| Next Q 2026-09-30 |
$-0.58 | $-1.04 | $-0.30 | 30.4% | -12.8% | 2↑ 2↓ | $0.0B | -77.9% | 6 |
| Current FY 2026-12-31 |
$-2.68 | $-4.34 | $-1.75 | 10.2% | -12.3% | 2↑ 1↓ | $0.0B | -94.3% | 6 |
| Next FY 2027-12-31 |
$-2.42 | $-4.60 | $-1.36 | 9.7% | -42.8% | 1↑ 2↓ | $0.0B | 212.5% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.785 | |
| 7d ago | $-0.785 | |
| 30d ago | $-0.581 | -0.204 |
| 60d ago | $-0.581 | -0.204 |
| 90d ago | $-0.502 | -0.283 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 22, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Roth Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Dec 18, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jan 29, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$CRVO – CervoMed Inc. - (Spoiler I am down 43%)
▲ 1
💬 0
⚡ 0.0
Jun 7, 2026
Clinical Trial
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase Phase 2 — COMPLETED
Jun 7, 2026
clinical_trial_readout
Results Pending: neflamapimod (Phase 2) — Completed 88d ago
Trial: A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor: EIP Pharma Inc
Phase: Phase 2 | Completed: 2026-03-11
Cond
May 19, 2026
earnings_calendar
CRVO Q1 2026 Earnings Scheduled — 2026-05-19
May 18, 2026
earnings
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies i
May 11, 2026
earnings_calendar
CRVO Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
clinical_trial_readout
Results Pending: neflamapimod (Phase 2) — Completed 58d ago
Trial: A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor: EIP Pharma Inc
Phase: Phase 2 | Completed: 2026-03-11
Cond
May 6, 2026
Clinical Trial
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase Phase 2 — COMPLETED
Apr 22, 2026
earnings
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
<p align="center"><em>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease p
Apr 7, 2026
routine
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
<p align="center"><em>Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and fi
Mar 19, 2026
other
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
<p align="center"><em>New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheime
Mar 17, 2026
earnings
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
<p align="center"><em>Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026</em></p>
Mar 16, 2026
earnings_calendar
CRVO Q4 2025 Earnings After Market Close — 2026-03-16
Mar 5, 2026
other
CervoMed to Participate in Upcoming Investor Conferences
<p>BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-rel
Mar 4, 2026
other
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies